Free Daily Podcast Summary
BioSpace: Daily Summaries Delivered
by BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Today17 min
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.
- 6 days ago20 min
Nordic biotech’s next act: From fragmentation to global force
In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsEster Sklarsky, Principal, Sound BioventuresJoão Ribas, Partner, Novo Holdings Seed InvestmentsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 1 weeks ago21 min
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.
- 1 weeks ago19 min
The future of pain relief: Exploring opioid alternatives
In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsLance Alstodt, Chairman & CEO, BioRestorative TherapiesPaul Mieyal, Chief Business Officer, South Rampart PharmaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 2 weeks ago21 min
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.
- 2 weeks ago9 min
Bonus: Q2 2026 Job Market Update
In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.
- 2 weeks ago20 min
From sequence to scale: Gene editing’s new era in biologics manufacturing
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJack Crawford, CEO, DemeetraMagnus Gustafsson, Chief Commercial Officer, NorthX BiologicsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 3 weeks ago17 min
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.
About BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from BioSpace in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's BioSpace daily summary?
It's a free AI-powered email that summarizes new episodes of BioSpace as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the BioSpace podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official BioSpace product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BioSpace.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does BioSpace release new episodes?
BioSpace publishes 2x weekly. Our AI generates a summary within hours of each new episode.
What topics does BioSpace cover?
BioSpace covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting BioSpace summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.